Companion diagnostics developer Foundation Medicine has launched FoundationOne Monitor, a tissue-naïve circulating tumor DNA (ctDNA) monitoring assay for research use in retrospective studies. The product provides insights into treatment response, resistance mechanisms, and ctDNA tumor fraction when tumor tissue is not available.

FoundationOne Monitor quantifies ctDNA tumor fraction at each time point, offering molecular response insights and assessing resistance to therapy across more than 300 genes. It complements standard imaging in early-phase clinical research and expands Foundation Medicine's monitoring portfolio. Also included in Foundation Medicine's monitoring portfolio is FoundationOne Tracker, a ctDNA test that utilizes tissue information which was launched in June 2021 for research purposes and in January 2023 for investigational use.

The key benefits of using FoundationOne Monitor include improved sensitivity, high specificity, and comprehensive insights on treatment response, variant studies, resistance mechanisms, and ctDNA tumor fraction. It complements the existing monitoring portfolio and positions Foundation Medicine as a one-stop shop for biopharma partners' treatment response in monitoring research needs.